Stockscreener 앱 받기
69.78
0.11%
-0.08
시간 외 거래:
69.78
전일 마감가:
$69.86
열려 있는:
$69.96
하루 거래량:
4.93M
Relative Volume:
1.06
시가총액:
$41.16B
수익:
$6.60B
순이익/손실:
$4.16B
주가수익비율:
10.07
EPS:
6.93
순현금흐름:
$490.10M
1주 성능:
-4.96%
1개월 성능:
-5.86%
6개월 성능:
-20.08%
1년 성능:
-5.47%
1일 변동 폭
$69.10
$70.28
1주일 범위
$68.23
$72.34
52주 변동 폭
$58.93
$96.12
에드워즈라이프사이언시스 Stock (EW) Company Profile
명칭
Edwards Lifesciences Corp
전화
(949) 250-2500
주소
ONE EDWARDS WAY, IRVINE, CA
EW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
|
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
에드워즈라이프사이언시스 Stock (EW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-16 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-09-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-31 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | Truist | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-03-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-02-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-28 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-03-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | 다운그레이드 | Bernstein | Outperform → Underperform |
| 2023-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 개시 | Mizuho | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-29 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 개시 | Truist | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-03-16 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-27 | 재확인 | Citigroup | Buy |
| 2022-01-27 | 재확인 | Evercore ISI | Outperform |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | Stifel | Buy |
| 2022-01-27 | 재확인 | UBS | Neutral |
| 2021-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-12-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-30 | 재확인 | Deutsche Bank | Hold |
| 2021-07-30 | 재확인 | Jefferies | Buy |
| 2021-07-30 | 재확인 | Morgan Stanley | Overweight |
| 2021-07-30 | 재확인 | Oppenheimer | Outperform |
| 2021-07-30 | 재확인 | Stifel | Buy |
| 2021-07-30 | 재확인 | UBS | Neutral |
| 2021-07-30 | 재확인 | Wells Fargo | Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-04-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-11 | 재확인 | Canaccord Genuity | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Underperform |
| 2020-04-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Outperform |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-09-23 | 개시 | Piper Jaffray | Overweight |
| 2019-07-24 | 재확인 | BofA/Merrill | Buy |
| 2019-03-18 | 재확인 | Canaccord Genuity | Buy |
| 2019-01-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Hold |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-10-02 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
모두보기
에드워즈라이프사이언시스 주식(EW)의 최신 뉴스
Edwards Lifesciences CVP Daniel Lippis sells $34,382 in stock - MSN
Seilern Investment Management Ltd Invests $109.49 Million in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Gateway Investment Advisers LLC Acquires 5,726 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Sees Significant Growth in Short Interest - MarketBeat
Boston Common Asset Management LLC Lowers Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
65,442 Shares in Edwards Lifesciences Co. (NYSE:EW) Purchased by Avanza Fonder AB - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) VP Sells $34,380.00 in Stock - MarketBeat
Edwards Lifesciences CVP Daniel Lippis sells $34,382 in stock By Investing.com - Investing.com Canada
Wolfe Research Downgrades Edwards Lifesciences (EW) - MSN
Edwards Lifesciences exec sells $343,735 in stock - Investing.com
Do You Believe in the Growth Prospects of Edwards Lifesciences Corporation (EW)? - MSN
West Coast Financial LLC Sells 9,846 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Wolfe Research cuts Edwards Lifesciences stock rating to Underperform - MSN
Wolfe Research Downgrades Edwards Lifesciences (NYSE:EW) to Underperform - MarketBeat
Should Edwards Lifesciences Stock Stay in Your Portfolio Now? - Yahoo Finance
Meril successful at EPO against Edwards Lifesciences in heart-valve battle - JUVE Patent
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Assenagon Asset Management S.A. Buys 3,506,886 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST Purchases 300,000 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences price target raised to $74 from $72 at Bernstein - MSN
Edwards Lifesciences’ Q4 2024 Earnings: What to Expect - Nasdaq
Edwards Lifesciences’ Q4 2024 Earnings: What To Expect - Barchart
Edwards Lifesciences Co. (NYSE:EW) Receives $79.40 Consensus Target Price from Analysts - MarketBeat
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Stock Price | EW Stock Quote, News, and History - Markets Insider
Brain Ischemia Market grow at CAGR of 7.6% Growth, Reaching $1,622 million by 2032 Globally - GlobeNewswire Inc.
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Nordea Investment Management AB Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) is largely controlled by institutional shareholders who own 85% of the company - Yahoo Finance
Edwards Lifesciences price target raised to $75 from $69 at Evercore ISI - Yahoo Finance
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE:EW) Share Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Edwards Lifesciences gets FDA warning letter - Reuters
Edwards Lifesciences Corporation (EW): Among the Cheap Healthcare Stocks to Buy Heading Into 2025 - Insider Monkey
Edwards Lifesciences Corp. stock rises Tuesday, still underperforms market - MarketWatch
Wolfe Research Upgrades Edwards Lifesciences (EW) - MSN
Edwards Lifesciences Corp. stock remains steady Monday, underperforms market - MarketWatch
Principal Financial Group Inc. Has $53.95 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Corporation's (NYSE:EW) Price Is Out Of Tune With Earnings - Simply Wall St
Jim Cramer: Is Edwards Lifesciences (EW) Poised for a Comeback? - Insider Monkey
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
EDWARDS ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Edwards lifesciences CVP Daniel Lippis sells $185k in stock By Investing.com - Investing.com Australia
Edwards Lifesciences' SWOT analysis: stock outlook amid TAVR challenges and TMTT growth - Investing.com
Edwards lifesciences CVP Daniel Lippis sells $185k in stock - Investing.com India
Daniel J. Lippis Sells 2,500 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock - MarketBeat
Assessing Edwards Lifesciences: Insights From 20 Financial Analysts - Benzinga
Edwards Lifesciences shares upgraded to buy, target lifted on trajectory - Investing.com
Bank of America Upgrades Edwards Lifesciences (NYSE:EW) to "Buy" - MarketBeat
에드워즈라이프사이언시스 (EW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.31%
0.27%
자본화:
|
볼륨(24시간):